Eli Lilly CEO on Obesity Drug Access, Medicare Pricing, and the Next-Generation Pipeline

Eli Lilly Chair and CEO Dave Ricks joins Jim to discuss the company's obesity care franchise, covering market expansion, affordability programs, persistence among patients, and the next wave of molecules in development. The conversation ties commercial results to access initiatives and pipeline progress.

■ Market Expansion and Oral Tirzepatide
- Estimate of global and U.S. obesity care penetration among eligible patients
- Four new molecules in Phase 3, with the oral tirzepatide rollout as the current focus

■ Affordability and Medicare Access
- The Medicare GLP-1 bridge program launching July 1, with $50 monthly out-of-pocket costs for seniors
- A third-party preprint estimating U.S. government savings over 10 years from greater obesity drug use

■ Persistence and Next-Generation Drugs
- Affordability and coverage as drivers of persistence, with low drop-off rates in the senior program
- A Phase 3 amylin receptor agonist program in enrollment, plus Phase 2 weight loss and tolerability results

Investors, healthcare professionals, and anyone following the obesity drug market will come away with a clear picture of how access, pricing, and pipeline innovation are shaping Eli Lilly's strategy. The discussion offers context for evaluating coverage trends, patient retention, and upcoming launches.